长效注射剂市场（2026—2031）
长效注射剂市场规模预计由2026年的215.9亿美元增至2031年的386.3亿美元，预测期复合年增长率为12.34%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
长效注射剂市场规模预计由2026年的215.9亿美元增至2031年的386.3亿美元，预测期复合年增长率为12.34%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 12.34% | 机构预测 |
| 市场规模 | 2026 | USD 21.59 billion | 机构预测 |
| 市场规模 | 2031 | USD 38.63 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| end_user | hospitals | 2025 | 45.670% |
| geography | North America | 2025 | 41.670% |
| molecule_type | small molecules | 2025 | 78.550% |
| route_of_administration | intramuscular delivery | 2025 | 72.670% |
| technology | polymer-based depot systems | 2025 | 42.450% |
| therapeutic_area | CNS disorders | 2025 | 45.230% |
关键结论
- end_user 维度中，hospitals 在 2025 年的公开份额为 45.67%。
- geography 维度中，North America 在 2025 年的公开份额为 41.67%。
- molecule_type 维度中，small molecules 在 2025 年的公开份额为 78.55%。
- route_of_administration 维度中，intramuscular delivery 在 2025 年的公开份额为 72.67%。
- technology 维度中，polymer-based depot systems 在 2025 年的公开份额为 42.45%。
- therapeutic_area 维度中，CNS disorders 在 2025 年的公开份额为 45.23%。
主要参与者
- Johnson & Johnson
- Alkermes plc
- Otsuka Pharmaceutical Co., Ltd.
- Indivior PLC
- Camurus AB
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Improved adherence and relapse prevention in chronic disease management | +2.800% | Global, strongest pull in North America and Europe | Medium term (2-4 years) |
| Expansion of long-acting HIV treatment and pre-exposure prophylaxis | +2.300% | North America and Sub-Saharan Africa, with spillover to Europe and Asia-Pacific | Short term (≤ 2 years) |
| Rising need for extended-release therapies in opioid use disorder | +1.500% | North America, Australia, and Northern Europe | Medium term (2-4 years) |
| Evidence for lower dosing burden and reduced hospitalization | +1.200% | Global, with faster uptake in payer-constrained settings | Medium term (2-4 years) |
| Formulation platforms enabling monthly-to-six-month dosing intervals | +1.400% | Global, led by United States, European Union, and Japan approvals | Long term (≥ 4 years) |
| Provider workflow and injection-visit infrastructure as an adoption lever | +0.900% | Urban North America, Western Europe, and advanced Asia-Pacific settings | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High acquisition cost and reimbursement complexity | -1.800% | North America, with growing relevance in Europe | Short term (≤ 2 years) |
| Injection-site reactions, administration burden, and limited reversibility | -1.000% | Global, with greater sensitivity in cost-restricted Asia-Pacific, Middle East, and Africa settings | Long term (≥ 4 years) |
| Manufacturing scale-up risk for sterile suspensions and complex depots | -0.900% | Global, especially for newer polymer and in-situ depot platforms | Medium term (2-4 years) |
| Missed-dose, bridging, and pharmacokinetic tail-management complexity | -0.700% | Global, with higher clinical risk in HIV and CNS care | Long term (≥ 4 years) |
报告关注的关键问题
What is driving demand for long acting injectables?
Demand is supported by the need to improve treatment continuity and reduce daily dosing, relapse, hospitalization, and discontinuation across chronic conditions.
How large is the long acting injectables market?
The long acting injectables market size is USD 21.59 billion in 2026 and is forecast to reach USD 38.63 billion by 2031 at a 12.34% CAGR.
Which therapeutic area leads long acting injectable use?
CNS disorders led with 45.23% share in 2025 because antipsychotic LAIs have a large and established treatment base.
Which route of administration is growing fastest?
Subcutaneous delivery is forecast to grow at a 13.45% CAGR from 2026 to 2031, supported by higher drug-loading and delivery advances.
Why are long acting HIV medicines important?
Cabenuva, Sunlenca, and Yeztugo provide dose intervals from monthly to twice yearly, creating more options for treatment and HIV prevention.
What limits wider use of long acting injectables?
High acquisition costs, coverage requirements, monitoring obligations, injection-site concerns, and complex sterile manufacturing can delay adoption.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence